Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

NCT00712881 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Liposomal doxorubicin hydrochloride
DRUG: Cyclophosphamide
DRUG: Trastuzumab
DRUG: Free doxorubicin hydrochloride
DRUG: Docetaxel

Sponsor

Cephalon, Inc.